Dummy Medicines, Dummy Doctors, and a Dummy Degree, Part 1: a Curious Editorial Choice for the New England Journal of Medicine

Every so often, a medical journal does something that makes perfectly sensible people blink like they just walked into a surprise mime convention. In July 2011, The New England Journal of Medicine (NEJM) published an asthma study that was, on the face of it, solid and genuinely interesting: compare a real rescue inhaler (albuterol) to a placebo inhaler, sham acupuncture, andmy personal favorite control conditionnothing. The results were a masterclass in the difference between feeling better and being better.

Then came the editorial accompaniment: a philosophical, context-heavy meditation on “meaningful placebos” written not by a pulmonologist, a clinical trialist, or even a curmudgeonly internist with a spice rack full of skepticism, but by an anthropologist. That pairing sparked the Science-Based Medicine (SBM) post with the unforgettable title you see aboveequal parts critique, warning label, and comedic groan.

This article is an in-depth, plain-English tour of what happened, why the study matters, why the editorial choice felt odd to many clinicians, and how the “dummy” framing touches three real-world hazards: placebo hype, credential confusion, and the very modern marketplace of health fraud. No pitchforks requiredjust curiosity, context, and a willingness to ask one annoying question: “Yes, but did it change the lungs?”

What the NEJM Asthma Study Actually Found (No Smoke, Just Spirometry)

The trial design was clever: a randomized, crossover study where participants with asthma cycled through four conditions across multiple visits: (1) active albuterol inhaler, (2) placebo inhaler, (3) sham acupuncture, and (4) no intervention. Researchers measured two categories of outcomes: an objective lung function testforced expiratory volume in one second (FEV₁)and subjective ratings of improvement.

Objective outcome: albuterol worked; the dummies didn’t

On the objective measure, albuterol did what bronchodilators do: it improved airflow. Participants had about a 20% increase in FEV₁ with albuterol, compared with roughly 7% with placebo inhaler, sham acupuncture, and no intervention. Translation: the real medicine opened airways in a way the sham options didn’t.

Subjective outcome: everybody felt betteralmost equallyif “something” happened

Now for the plot twist: when asked how much better they felt, participants reported similar improvements with albuterol, the placebo inhaler, and sham acupuncture. The “no intervention” arm lagged far behind. Translation: ritual and expectation can dramatically improve perceived symptoms, even when airflow doesn’t budge.

The study’s own punchline was basically: patient-reported outcomes can be unreliable in asthma if you don’t account for placebo response and natural variability. That’s not an insult to patientsit’s a reminder that the brain and body keep separate ledgers.

Why This Study Became Catnip for Two Opposing Crowds

If you’ve ever watched two people read the same headline and walk away with opposite conclusions, welcome to health discourse. This paper offered both sides something to grab:

• Science-based clinicians and skeptics saw strong evidence that sham acupuncture was indistinguishable from placebo and that objective measures matter. “Feeling better” is real and important, but asthma is also a disease where airflow limitation can become dangerous fast.
• CAM/integrative medicine boosters saw a shiny object: “Sham acupuncture works as well as albuterol!” That statement is only “true” if you ignore the part where albuterol improved lung function and sham acupuncture didn’t. It’s like claiming a cardboard umbrella is as good as a raincoat because both make you feel optimistic.

This is the core tension the SBM authors were warning about: when you elevate subjective improvement above objective physiology, you create a friendly habitat for elaborate placebos. And elaborate placebos tend to show up wearing lab coats.

The “Curious Editorial Choice”: What Was the Fuss About?

In SBM’s “Dummy Medicines, Dummy Doctors, and a Dummy Degree, Part 1,” physician-author Kimball Atwood focused less on the trial (which he largely respected) and more on the editorial pairing. NEJM’s editor-in-chief at the time was a pulmonologist; the study was about asthma; the editorial was written by Daniel Moerman, PhD, known for reframing placebo as a “meaning response.” The criticism wasn’t that anthropology is uselessfar from it. The criticism was about what happens when a top-tier medical journal gives an editorial megaphone to an interpretation that can be easily weaponized by people selling non-evidence-based care.

Editorials aren’t neutral; they are the journal’s “voice-over narration.” A trial can be careful and nuanced, but an editorial can turn nuance into a slogan. And slogans travel. Nuance usually misses the bus.

A fair defense of NEJM (yes, really)

To be fair to the concept, there’s a legitimate question here: if patient experience improves with context and expectation, should clinicians harness that ethically? Should we build better therapeutic relationships, use clearer reassurance, create calmer care environments, and communicate in ways that reduce fear and improve adherence? Absolutely. That’s not quackery. That’s… basic bedside manner, upgraded.

The problem is the bait-and-switch that follows: “context matters” becomes “therefore the fake treatment works.” The moment you make that leap, you’ve left patient-centered care and entered a carnival of shiny props.

Dummy Medicines: Placebos, “Meaning,” and the Limits of Feeling Better

The placebo effect isn’t “imaginary.” It’s better described as a psychobiological response to expectation, conditioning, and the therapeutic context. In plain terms: if you strongly anticipate relief, and the care ritual signals safety and competence, your symptomsespecially subjective ones like pain, nausea, anxiety, and breathlessnesscan genuinely shift.

But here’s the key boundary line: placebo responses are not a universal substitute for disease-modifying treatment. In conditions where objective physiology is the danger (asthma, infections, diabetes, heart failure), symptom relief without physiologic improvement can be risky. You might feel calmer while your oxygen levels do something unfunny.

The NEJM asthma study dramatized this boundary beautifully. People felt better with placebo rituals. Only albuterol measurably opened airways. A journal can explore that tension responsiblyas long as readers are constantly reminded which outcomes changed and which didn’t.

Sham Acupuncture: When the Needle Is the Message

Sham acupuncture is a fascinating research tool because it functions like a theatrical understudy: it looks like the “real” act, but it’s designed not to deliver the specific mechanism. If sham and real acupuncture perform similarly, the most plausible conclusion is that the ritualnot the meridiansdid the heavy lifting.

Even US government health resources summarize the evidence with a careful split: acupuncture may help with symptoms or quality of life for some conditions, but it often does not outperform sham proceduresand for asthma specifically, it may improve quality of life while not improving lung function. That distinction is exactly the point the asthma trial made with spirometry: subjective relief can be real, yet physiologic airflow can remain unchanged.

Dummy Doctors: Credential Confusion and the “White Coat Halo”

The phrase “dummy doctors” in the SBM title is intentionally provocative, but the underlying concern is serious: people who market themselves as “doctor” can range from licensed physicians to highly trained non-physician clinicians to unlicensed practitioners with impressive-sounding titles. The public doesn’t always know the differenceand scammers love that.

Here’s where the NEJM editorial concern becomes practical: when elite medical brands appear to “validate” placebo-based interpretations, it gives permission slips to practitioners who already prefer rituals over results. Some will go further and recommend unproven asthma “fixes” that sound gentle and natural and arehow to put this kindlyuninterested in evidence. Asthma is not the disease you want to treat with vibes.

How to spot the halo effect in the wild

• Big promises: “Works for everyone.” “Cures the root cause.” “No side effects.”
• Prestige laundering: name-dropping famous journals or universities as a substitute for good data.
• Outcome swapping: highlighting “patients felt better” while ignoring “the disease marker didn’t change.”
• Authority cosplay: white coats, stethoscopes, and certificates that look like they came from an office supply store with a laminator.

None of this means every nontraditional therapy is automatically a scam. It means that when claims touch serious disease, the burden of proof gets heavierand should. The more dangerous the condition, the less you can afford a treatment that only improves the story.

Dummy Degrees: Diploma Mills, “Doctor” Titles, and Why Verification Matters

The “dummy degree” part of the title points at a parallel problem: degrees and credentials can be real, questionable, or flat-out fabricated. The Federal Trade Commission and the U.S. Department of Education both warn consumers about diploma millsoperations that sell degrees with little or no legitimate coursework, often using sound-alike names and slick websites.

This matters in health because a fancy title is a powerful marketing shortcut. If your business model depends on patients not knowing how licensure works, you’re not practicing medicineyou’re practicing misdirection.

Practical verification (because your lungs deserve due diligence)

1. Verify licensure: check your state medical board’s physician profile system.
2. Use national tools: the Federation of State Medical Boards (FSMB) provides consumer guidance and access to consolidated physician licensure and disciplinary information via its DocInfo service.
3. Check scope: ask what the clinician is licensed to do in your state and whether they’re practicing within training.
4. Beware title soup: letters after a name are not interchangeable; “doctor” is not one uniform category in U.S. healthcare.

The point isn’t paranoia. The point is proportion: if someone is advising you to change asthma medication, you should know whether they’re qualified to do that. “Trust me” is not a credentialing system.

Where Dummy Medicine Gets Dangerous: Health Fraud and Counterfeit Drugs

The modern health marketplace has two overlapping threats: fake claims and fake products. The FTC describes common health scams as products that claim to cure many conditions, rely on fake endorsements, and push urgency or miracle results. The FDA warns consumers about counterfeit medicines and notes the risks of buying from unsafe online pharmacies.

This isn’t theoretical. Public health agencies have warned that people ordering “prescription” pills from illegal online pharmacies may receive counterfeit products that contain dangerous substances (including potent opioids), putting them at risk of overdose. That’s the nightmare version of a placebo: you expect help, you get harm, and the packaging looks legit enough to fool a tired human being at 11:47 p.m.

If the SBM post’s title feels dramatic, remember: it’s dramatizing a real chain of events. A journal editorial nudges a narrative. The narrative becomes marketing. Marketing becomes behavior. Behavior can become injury.

So What Should Medical Journals Do With Placebo Findings?

Placebo research is valuable. It teaches us how context shapes symptom perception, adherence, and patient satisfaction. It can help clinicians reduce suffering without deceptionthrough better communication, empathy, and care design.

But journals also have a responsibility to prevent interpretive drift, especially when publishing in areas that overlap with “integrative” branding. A few guardrails help:

• Keep objective and subjective outcomes distinctand say, repeatedly, why that distinction matters.
• Anticipate misuse: if a finding can be weaponized into “fake treatments work,” address that explicitly.
• Avoid prestige laundering: don’t let a journal’s reputation become free advertising for placebo-based practice models.
• Center patient safety: especially for conditions like asthma where delayed effective treatment can be dangerous.

In other words: talk about meaning, surebut don’t let meaning replace mechanism when mechanism is the difference between breathing and not.

Quick Reader Toolkit: How Not to Get Fooled by “Dummy” Logic

Next time you see a headline like “Placebo works as well as drug,” run these questions:

• What outcomes improved? Symptoms, biomarkers, survival, lung function, imaging findings?
• What was the control? Placebo, sham procedure, usual care, or no intervention?
• Was it safe to generalize? Mild disease in a trial is not the same as severe disease in real life.
• Who is interpreting it? Are they selling a service, a supplement, a course, or a “certification”?
• Does the interpretation match the data? If not, you’re reading marketing, not medicine.

Conclusion: The Editorial Choice Was “Curious” Because the Stakes Are Real

The NEJM asthma trial gave us a crisp lesson: placebo rituals can move subjective experience, but objective lung function still tells the truth about airflow. The SBM “Dummy Medicines” critique wasn’t just about academic sniping; it was about how easily placebo narratives spill into clinical culture, where they can justify weak treatments, confuse credentials, and feed an already noisy market of health fraud.

The real takeaway is not “placebos are useless” or “patients are imagining things.” It’s this: patient experience matters, and physiology matters, and pretending they’re the same is how people get hurt. If your “treatment” can’t change the disease, it shouldn’t be allowed to cosplay as oneno matter how prestigious the stage lighting.

Experiences Related to “Dummy Medicines, Dummy Doctors, and a Dummy Degree” (500-ish Words)

Picture a familiar scene: someone with mild asthma feels tight-chested after a dusty day. They use their rescue inhaler and feel better. Straightforward. Now replay the scene with a twist: they watch a slick video about “natural breathing fixes” and order a kit that arrives with a booklet, a bracelet, and a certificate proclaiming the creator a “doctor of holistic pulmonary alignment” (which sounds like a Marvel villain, if we’re being honest). They try the ritual during the next flare. The calm music starts. The breathing slows. Anxiety drops. The person reports, sincerely, “I feel a lot better.” And they mightbecause breathlessness is partly sensation and partly physiology, and sensations respond powerfully to reassurance and focus.

This is how placebo responses become personally persuasive. When you feel relief, you naturally credit what you just did. Humans are narrative machines. We build stories first and footnotes later. If the flare would have eased anywayor if the ritual reduced panic while airway narrowing remained unchanged the story still feels true in the moment. That’s not stupidity. That’s normal cognition in a body that wants to breathe comfortably.

Another common experience shows up in how people talk about acupuncture and sham treatments. Many patients describe the appointment itself as a kind of therapeutic theater: a quiet room, a confident practitioner, careful attention, and the sense that someone is finally listening. Even skeptics can admit that this context can feel healing. The danger starts when the emotional truth of that experience is swapped for a medical claim: “Therefore the needles fixed my lungs,” or worse, “Therefore I don’t need my inhaler.” The first statement may be a misunderstanding; the second can become a crisis.

Credential confusion is its own lived experience. People often assume that “doctor” means “licensed physician,” and that assumption is reinforced by the white coat, the framed diplomas, and the receptionist who calls the practitioner “Doctor” with the same tone used for royalty. Then a friend says, “Wait, is that an MD? A DO? A chiropractor? A naturopath? A PhD?” Suddenly the patient realizes they never thought to ask. In a world where legitimate clinicians exist alongside confident impersonators and aggressive marketers, that’s not a moral failingit’s an information gap.

The internet adds another layer: the late-night pharmacy purchase, the “discount” price, the site that looks official enough, and the quiet hope that you can solve a health problem without another appointment. Public health warnings about counterfeit medicines sound abstract until you imagine someone taking a pill they believe is a routine prescriptiononly to discover it’s not routine, not regulated, and not safe. In that moment, the line between “dummy” and “deadly” stops being rhetorical.

The most constructive experience-based lesson is also the simplest: keep the human parts of care (time, attention, reassurance, empathy) while refusing to outsource physiology to placebo theater. You deserve clinicians who can offer both: the comfort of being heard and the competence of treatments that measurably work. Anything less is just stagecraftand your lungs are not an audience.